TransCon IL-2 β/​γ in Locally Advanced or Metastatic Solid Tumor Malignancies

What is the Purpose of this Study?

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called TransCon IL-2 beta/gamma when given in combination with chemotherapy or in combination with another experimental drug, TransCon TLR7/8 Agonist, for the treatment of advanced cancer. Specifically, researchers aim to determine whether the addition of TransCon IL-2 beta/gamma or TransCon TLR7/8 Agonist leads to better outcomes for patients with platinum-resistant ovarian cancer or recurrent/metastatic (cancer that has spread to other parts of the body) cervical cancer. Researchers will also examine the effect of the drugs on the patient's cancer by conducting biomarker studies. Biomarkers are important biological indicators that can be measured from blood and tumor tissues.


Eligibility

  • At least 18 years of age
  • Demonstrated adequate organ function at screening
  • Life expectancy >12 weeks as determined by the Investigator
  • Female and male participants of childbearing potential who are sexually active must agree to use highly effective methods of contraception
Show more

Where can I participate?

Cedars-Sinai Cancer at SOCC

More about this Clinical Trial

What is the full name of this clinical trial?

ASND0029 IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 beta/gamma Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies

Study Details
Disease Type/Condition

Ovary

Principal Investigator

Rimel, Bobbie Jo

Co-Investigators

Andrew Li, Kamya Sankar, Kenneth Kim, Kristin Taylor, Margaret Liang

Age Group

Adult

Phase

I/II

IRB Number

STUDY00002814

ClinicalTrials.gov ID

NCT05081609

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Ovary

Principal Investigator

Rimel, Bobbie Jo

Age Group

Adult

Phase

I/II

IRB Number

ASND0029

ClinicalTrials.gov ID

NCT05081609

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org